Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven M Devine

Showing results (141-150 of 178) with videos related to

Pageof 18
Sort By:
JCO Precision Oncology|May 26, 2021
Impact of Conditioning Intensity and Genomics on Relapse After Allogeneic Transplantation for Patients With Myelodysplastic SyndromeLaura W Dillon, Gege Gui, Brent R Logan, et al.
Blood Advances|May 26, 2018
Related donor transplants: has posttransplantation cyclophosphamide nullified the detrimental effect of HLA mismatch?Tara M Robinson, Ephraim J Fuchs, Mei-Jie Zhang, et al.
Blood|May 5, 2017
PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHDBradley M Haverkos, Diana Abbott, Mehdi Hamadani, et al.
Transplantation and Cellular Therapy|July 6, 2025
Allogeneic Hematopoietic Cell Donor Selection: Contemporary Guidelines from the NMDP/CIBMTRAntonio M Jimenez Jimenez, Stephen R Spellman, Ioannis Politikos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 2, 2021
Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor-Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic MalignanciesLeo Luznik, Marcelo C Pasquini, Brent Logan, et al.
Blood Advances|March 21, 2019
Plerixafor alone for the mobilization and transplantation of HLA-matched sibling donor hematopoietic stem cellsYi-Bin Chen, Jennifer Le-Rademacher, Ruta Brazauskas, et al.
Blood|March 13, 2012
Regulation of acute graft-versus-host disease by microRNA-155Parvathi Ranganathan, Catherine E A Heaphy, Stefan Costinean, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 11, 2015
Atorvastatin for the Prophylaxis of Acute Graft-versus-Host Disease in Patients Undergoing HLA-Matched Related Donor Allogeneic Hematopoietic Stem Cell Transplantation (allo-HCT)Yvonne A Efebera, Susan Geyer, Leslie Andritsos, et al.
Blood Advances|February 25, 2020
KIR B donors improve the outcome for AML patients given reduced intensity conditioning and unrelated donor transplantationDaniel Weisdorf, Sarah Cooley, Tao Wang, et al.
JAMA Oncology|May 2, 2024
Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid LeukemiaLaura W Dillon, Gege Gui, Niveditha Ravindra, et al.
Pageof 18

Showing results (141-150 of 178) with videos related to

Sort By:
Pageof 18
JCO Precision Oncology|May 26, 2021
Impact of Conditioning Intensity and Genomics on Relapse After Allogeneic Transplantation for Patients With Myelodysplastic SyndromeLaura W Dillon, Gege Gui, Brent R Logan, et al.
Blood Advances|May 26, 2018
Related donor transplants: has posttransplantation cyclophosphamide nullified the detrimental effect of HLA mismatch?Tara M Robinson, Ephraim J Fuchs, Mei-Jie Zhang, et al.
Blood|May 5, 2017
PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHDBradley M Haverkos, Diana Abbott, Mehdi Hamadani, et al.
Transplantation and Cellular Therapy|July 6, 2025
Allogeneic Hematopoietic Cell Donor Selection: Contemporary Guidelines from the NMDP/CIBMTRAntonio M Jimenez Jimenez, Stephen R Spellman, Ioannis Politikos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 2, 2021
Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor-Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic MalignanciesLeo Luznik, Marcelo C Pasquini, Brent Logan, et al.
Blood Advances|March 21, 2019
Plerixafor alone for the mobilization and transplantation of HLA-matched sibling donor hematopoietic stem cellsYi-Bin Chen, Jennifer Le-Rademacher, Ruta Brazauskas, et al.
Blood|March 13, 2012
Regulation of acute graft-versus-host disease by microRNA-155Parvathi Ranganathan, Catherine E A Heaphy, Stefan Costinean, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 11, 2015
Atorvastatin for the Prophylaxis of Acute Graft-versus-Host Disease in Patients Undergoing HLA-Matched Related Donor Allogeneic Hematopoietic Stem Cell Transplantation (allo-HCT)Yvonne A Efebera, Susan Geyer, Leslie Andritsos, et al.
Blood Advances|February 25, 2020
KIR B donors improve the outcome for AML patients given reduced intensity conditioning and unrelated donor transplantationDaniel Weisdorf, Sarah Cooley, Tao Wang, et al.
JAMA Oncology|May 2, 2024
Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid LeukemiaLaura W Dillon, Gege Gui, Niveditha Ravindra, et al.
Pageof 18